Mounjaro and endometriosis: what we know, what we don't, and what to discuss with a prescriber

What the research actually shows about GLP-1 agonists and endometriosis

Most of the interest in tirzepatide for endometriosis stems from preclinical and early observational research into GLP-1 receptor agonists more broadly. Endometriosis is driven partly by chronic inflammation, and laboratory studies have found that GLP-1 receptor activation can suppress several pro-inflammatory signalling pathways, including those involving interleukin-6 and TNF-alpha. Some researchers have proposed this could, in theory, reduce the inflammatory environment that allows endometrial tissue to implant and grow outside the uterus.

That is a hypothesis, not a conclusion. As of mid-2026, no large randomised controlled trial has tested semaglutide or tirzepatide specifically against endometriosis in humans, and neither the MHRA, NICE nor any major UK clinical guideline has assessed these medicines for this condition. The evidence base that does exist for tirzepatide relates to metabolic health: in the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults with obesity achieved an average body-weight reduction of around 20–21% at the highest dose over 72 weeks. What that weight loss does to hormone-sensitive conditions is a related but distinct question.

A common misconception is that because Mounjaro affects hormones, it must directly target the oestrogen pathways implicated in endometriosis. It doesn't work that way. Tirzepatide acts on GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control; any downstream hormonal effect comes through the indirect route of reduced adipose tissue, not a targeted endocrine action.

How weight loss through Mounjaro may matter for people with endometriosis

Adipose (fat) tissue is itself an endocrine organ, it produces oestrogen through a process called aromatisation. In people with obesity, elevated oestrogen from this source can worsen hormone-sensitive conditions, including endometriosis. Reducing adipose tissue through sustained weight loss therefore reduces one source of circulating oestrogen, which may soften symptoms over time.

This is not a trivial point, and it is why some people with both obesity and endometriosis find that weight loss, whatever its route, changes their symptom picture. But it is also not the same as saying Mounjaro treats endometriosis. The medicine's job, in its licensed indication, is weight management. You can read a fuller account of how Mounjaro may interact with menstrual cycles and reproductive hormones, which covers the hormonal context in more detail.

For people with endometriosis who also meet the criteria for weight-management treatment, the NHS's tirzepatide information sets out what the medicine does, its common side effects and the groups for whom it is not recommended. A prescriber assessing your suitability would consider your full medical and surgical history, your current hormonal treatments, and any other conditions before deciding whether Mounjaro is appropriate.

Practical considerations: endometriosis medications and Mounjaro together

Many people with endometriosis take hormonal treatments, combined oral contraceptives, progestogens, or GnRH analogues. Tirzepatide slows gastric emptying, which can reduce the absorption rate of oral medications taken at the same time. For oral contraceptives specifically, the Mounjaro guidance recommends adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because pill absorption may be affected during that period.

This interaction is worth discussing openly with a prescriber, especially if your hormonal therapy is central to controlling your endometriosis. It does not mean the combination is impossible, it means it needs proper clinical oversight. If you are also thinking about the financial picture, context on how UK Mounjaro pricing works may help you plan.

Conditions that share pathways with endometriosis, such as polycystic ovary syndrome and metabolic syndrome, are also areas where tirzepatide research is active. Our prescribers also field questions about Mounjaro and immune-mediated conditions and tirzepatide's emerging role in fibrotic disease, both areas where early research is moving quickly, just as it is with endometriosis.

What to bring to a prescriber conversation

If you have endometriosis and are considering Mounjaro for weight management, the most useful thing you can do before a consultation is compile a clear picture of your current treatment plan: which hormonal therapies you take, any recent surgery, your symptom control, and any fertility intentions. This matters because some GnRH analogues affect bone density over time, and the relationship between Mounjaro and bone health is a separate question worth raising.

Pregnancy is a particularly important consideration. Tirzepatide is not recommended during pregnancy, while breastfeeding, or when trying to conceive. The MHRA advises effective contraception during treatment and for a wash-out period before attempting conception. If endometriosis has affected your fertility plans, this timing question deserves careful discussion with both your gynaecologist and your prescribing clinician.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day you submit it. If you'd like to discuss whether Mounjaro is appropriate given your situation, speak to our prescribers via a free consultation.